This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
REVIEW
Ethics of early diagnosis of neurodegenerative diseases under ontological uncertainty
Pirogov Russian National Research Medical University (RNRMU)
Correspondence should be addressed: Diana F Abdullaeva
Ostrovityanova St., Bldg. 1, Moscow, 117997, Russia; ur.xednay@7avealludbaanaid
Financing: this research was supported by the Russian Science Foundation (grant no. 26-18-00593), https://rscf.ru/project/26-18-00593/
The rapid aging of the population and development of early diagnostic technologies for neurodegenerative diseases pose new ethical challenges. By 2026, genetic and biomarker testing methods for predisposition to Alzheimer’s disease (AD) and Parkinson’s disease (PD) had become clinically available. However, their adoption has outpaced the development of ethical, legal, and social mechanisms for their responsible use. This article analyzes two sets of ethical issues related to the early diagnosis of AD and PD in the context of an “aging society.” The first group is related to presymptomatic testing in the absence of effective prevention methods. This includes the ethical dilemma of “to know or not to know,” the right to information and the right “not to know,” psychological risks (82% of physicians note a high level of stress in tested patients), social stigmatization (70% of physicians report it) and discrimination, as well as legal gaps in the protection of biomarker data. The second group of dilemmas stems from the ontological uncertainty of mild cognitive impairment (MCI), a condition situated on the borderline between physiological aging and pathology. The risks of overdiagnosis and unwarranted intervention, the problem of “psychological continuity” of personality and challenges of respecting autonomy in patients with cognitive impairments (the inability of roughly 20% of individuals with MCI to provide informed consent) are explored. The following ethical guidelines are proposed: improving informed consent, establishing a system for long-term psychosocial support, expanding legal protections for biomarker data, and reducing stigmatization within the framework of the active longevity concept.
Keywords: Alzheimer’s disease, Parkinson’s disease, stigmatization, informed consent, discrimination, early diagnosis, presymptomatic testing, mild cognitive impairment, ontological uncertainty, aging society